Introduction {#sec1-1}
============

F-18 fluoro-deoxyglucose (FDG) is a time-tested molecular imaging radiopharmaceutical used in positron emission tomography computed tomography (PET CT) imaging with many applications in the field of oncology such as cancer staging, evaluation of unknown primary cancer, treatment response, and recurrence evaluation.\[[@ref1]\] PET CT scan with F-18 FDG is technically demanding protocol-based test, as the image quality may be influenced by various factors such as physical exercise, brown fat activation, hyperglycemia, hyperinsulinemia, inflammation, and thyrotoxicosis.\[[@ref2][@ref3]\]

In diabetes mellitus (DM) patients, plasma glucose levels and serum insulin levels will affect the biodistribution of F-18 FDG. Increased glucose levels decrease the F-18 FDG uptake in the tumors because F-18 FDG and glucose compete for glucose transport and phosphorylation by hexokinase. Hyperinsulinemia in response to elevated blood glucose causes rapid shunting of F-18 FDG to organs with high density of insulin receptors (e.g., skeletal and cardiac muscles) by increased translocation of glucose transporter-4 (GLUT4), thereby resulting in altered radiotracer biodistribution and suboptimal image quality.\[[@ref4]\] Therefore, preparation of DM patients with cancer requires more meticulous care, as some patients may report with high blood glucose levels on the day of test.

F-18 FDG PET CT scan is usually performed following the procedure guidelines prescribed by the European Association of Nuclear Medicine and Molecular Imaging and Society of Nuclear Medicine.\[[@ref1][@ref5]\] It is ideal to reschedule the patients for PET CT scan during conditions of hyperglycemia and hyperinsulinemia; however, rescheduling delays the diagnosis and also adds on to the financial burden of the center. In literature, to overcome these, some alternative methods using various insulin protocols have been proposed to prepare the patient.\[[@ref6]\]

The use of insulin lowers fasting blood glucose (FBG) levels in DM patients presenting with hyperglycemia; however, if F-18 FDG injection was given before the complete physiological neutralization of insulin, it may cause suboptimal image quality with uptake in muscles and soft tissue.\[[@ref7]\] Therefore, the present study was designed to use short-acting intravenous (IV) insulin to lower hyperglycemia, and timing of F-18 FDG injection was delayed to 90 min, postinsulin therapy to obtain the optimal image quality.

Materials and Methods {#sec1-2}
=====================

Ethics approval was obtained from the Institutional Ethics Committee.

Study design {#sec2-1}
------------

The design was a prospective interventional study.

Study population {#sec2-2}
----------------

A total of 613 patients referred for F-18 FDG whole-body PET CT scan who met the inclusion criteria \[[Table 1](#T1){ref-type="table"}\] were prospectively studied. Written informed consent was obtained from all patients. FBG levels were estimated, and patients were divided into three groups, namely Group I: DM patients with FBG \>160 mg/dL (known diabetics or incidentally diagnosed), Group II: DM patients with FBG \<160 mg/dL (100--160 mg/dL), and Group III: nondiabetic patients with normal FBG (\<100 mg/dL).

###### 

Inclusion and exclusion criteria of the study population

  Inclusion criteria                                          Exclusion criteria
  ----------------------------------------------------------- ----------------------------------------------------------
  All cancer patients of either gender, age (years) \>18-80   Patients not willing to participate in the study
  Patients willing to participate in the study                Inflammation, infection, or trauma in the gluteal region
  FBG \>280 mg/dL                                             
  Pregnancy                                                   
  Nursing mothers                                             
  Recent antiretroviral therapy (HAART)                       
  Neuromuscular disorders                                     

HAART: Highly active antiretroviral therapy, FBG: Fasting blood glucose

Patient preparation and insulin administration {#sec2-3}
----------------------------------------------

All patients in Group I were given short-acting IV insulin (injection human insulin 40 IU/mL) diluted in 10 mL normal saline, using a sliding scale \[[Table 2](#T2){ref-type="table"}\]. Patients with FBG \>280 mg/dL were excluded from the study. Postinsulin therapy blood glucose monitoring was done at every 30 min till 90 min, and all precautions were taken to treat patients with hypoglycemia. All patients in three groups were given 370 MBq (10 mCi) of F-18 FDG through IV cannula. Group I patients received F-18 FDG injection after 90 min of insulin therapy. In all other patients (Groups II and III), scan was acquired 60 min post F-18 FDG injection.

###### 

Sliding scale for intravenous insulin in Group I patients

  Glucose level (mg/dL)   Insulin dose (U)
  ----------------------- ------------------
  160-180                 4
  180-200                 6
  200-220                 8
  220-240                 10
  240-260                 12
  \>260                   14

Acquisition protocol and image analysis {#sec2-4}
---------------------------------------

Images were obtained in caudocranial orientation of supine position, covering body from thigh to vertex on a dedicated Siemens PET CT scanner (Biograph-06). PET CT images were analyzed visually, and FDG biodistribution was graded on a five-point scale \[[Table 3](#T3){ref-type="table"}\] as described earlier in similar type of the study.\[[@ref6][@ref8]\] Quantitative F-18 FDG uptake, that is, maximum standard uptake values (max SUVs) of cerebellum, cardiac muscle, liver, skeletal muscle, and fat tissue were obtained by manually drawing three-dimensional (3D) region of interest (ROI) in transaxial images \[[Figure 1](#F1){ref-type="fig"}\].

###### 

Biodistribution score for visual image analysis

  Pattern of FDG biodistribution                                       Score
  -------------------------------------------------------------------- -------
  Normal biodistribution                                               0
  Mild muscular uptake                                                 1
  Muscular uptake involving ≥1 muscle group                            2
  Diffuse muscular uptake of moderate intensity                        3
  Diffuse, intense muscular uptake causing nondiagnostic examination   4

FDG: Fluorodeoxyglucose

![F-18 fluorodeoxyglucose positron emission tomography maximum intensity projection image (a), positron emission tomography and positron emission tomography computed tomography axial images showing representative region of interests drawn over the brain (b and c), heart (d and e), liver (f and g), muscle (h and i), and fat tissue (j and k), respectively](IJNM-35-110-g001){#F1}

Statistical analysis {#sec2-5}
--------------------

Demographic data were represented as mean ± standard deviation (SD). To compare pre-insulin FBG and postinsulin FBG levels, paired "t" test was used. Chi-square test was used to compare the biodistribution score among three Groups. *P* \< 0.05 was considered statistically significant. Mean ± SD of different variables (max SUV in various ROIs) was obtained. For comparison of variables among groups, one-way ANOVA test was used.

Results {#sec1-3}
=======

Total study population was 613 patients. Characteristics of the study population are described in [Table 4](#T4){ref-type="table"}. In Group I, a total of 30 patients were included who had FBG levels \>160 mg/dL, with mean ± SD values of 214 ± 25.1 mg/dL. Among them, 18/30 (60%) were known diabetics, and 12/30 (40%) patients were detected incidentally with high FBG levels on the day of PET CT scan.

###### 

Characteristics of study population (*n*=613)

  Patient characteristics        Mean + SD, No of patients (*n*)
  ------------------------------ ---------------------------------
  Age (years), mean±SD (range)   55±12 (30-80)
  Sex^a^                         
   Female                        334 (55)
   Male                          279 (45)
  Groups^a^                      
   Group I                       30 (5)
   Known DM                      18
   *De novo* DM                  12
   Group II                      349 (55)
   Known DM                      349
   Group III                     234 (40)

^a^Values are represented as *n*. DM: Diabetes mellitus, SD: Standard deviation

In Group I patients, IV short-acting insulin was given according to the glycemic correction sliding scale \[[Table 2](#T2){ref-type="table"}\]. The mean glucose levels at 60 min after IV insulin decreased from 216 ± 22.2 to 136 ± 13.4 mg/dL \[[Table 5](#T5){ref-type="table"}\]; it indicates that insulin doses were adequate, and there was statistically significant decrease (*P* \< 0.05 using paired *t*-test) in postinsulin glucose levels. All patients in Group I tolerated IV insulin well; none of them developed hypoglycemia.

###### 

Comparison of blood glucose levels preinsulin and postinsulin

  Preinsulin and Postinsulin FBG levels   Mean + SD, Range   Paired *t*-test (*P*)
  --------------------------------------- ------------------ -----------------------
  Preinsulin (mg/dL)                                         \<0.05
   FBG, mean±SD                           216±22             
   Range                                  182-260            
  Postinsulin (mg/dL)                                        
   FBG, mean±SD                           136±13             
   Range                                  110-168            

SD: Standard deviation, FBG: Fasting blood glucose

Visual image analysis \[[Table 3](#T3){ref-type="table"}\] showed acceptable quality of PET CT images in all patients with a score of "0" or "1" based on biodistribution scores (acceptable score 0, 1, and 2 and unacceptable score "3" and "4"). In Group I patients, 15/30 showed score 0, and other 15/30 showed score 1 (acceptable image quality with mild soft-tissue uptake).

Quantitative parameters and max SUV were obtained for all patients by drawing identical 3D ROI in transaxial PET CT images as shown in [Figure 1](#F1){ref-type="fig"}. at brain (cerebellum), heart, liver, skeletal muscle, and fat. Mean ± SD values of max SUV of different regional variables, respectively, are shown in [Table 6](#T6){ref-type="table"}. One-way ANOVA analysis for variables showed statistically significant intergroup difference with *P* \< 0.05 \[[Table 6](#T6){ref-type="table"}\].

###### 

Maximum standardized uptake value over different region of interests

  ROI      Groups    Mean of max SUV + SD   Frequency   *P*
  -------- --------- ---------------------- ----------- -------
  Brain    I         6.1±1.8                30          0.000
  II       8.2±2.1   349                                
  III      8.7±2.3   234                                
  Heart    I         2.9±1.8                30          0.007
  II       3.7±2.9   349                                
  III      4.4±3.6   234                                
  Liver    I         2.9±0.6                30          0.000
  II       2.8±0.7   349                                
  III      2.4±0.6   234                                
  Muscle   I         1.0±0.3                30          0.001
  II       0.8±0.5   349                                
  III      0.6±0.2   234                                
  Fat      I         0.4±0.2                30          0.001
  II       0.4±0.1   349                                
  III      0.3±0.1   234                                

ANOVA was used to analyze the differences between group means. Bold values were statistically significant. ANOVA: Analysis of variance, ROI: Region of interest, max SUV: maximum standardized uptake value, SD: standard deviation

Discussion {#sec1-4}
==========

PET CT requires meticulous patient preparation as image quality may be influenced by machinery error, patient disease status, comorbid illness such as diabetes (high FBG levels), medications, radioactivity administered, extravasation, and variation in imaging protocols.\[[@ref9][@ref10]\]

Various types of insulin include long acting, intermediate acting, short acting, and rapid acting; among them, short-acting insulin will have onset of action at 30--60 min.\[[@ref11]\] Insulin decreases FBG levels by acting through GLUT receptors. Insulin-independent GLUT receptors are GLUT 1 (red blood cell, brain, and cornea), 2 (beta cells of pancreas, liver, and small intestine), 3 (brain and placenta), and insulin dependent are GLUT 4 (skeletal muscle and fat). Insulin can be administered subcutaneous (SC) or IV routes. Administration of SC insulin causes increased muscular uptake as documented in Garcia *et al*.\'s study;\[[@ref12]\] it also requires more time delay for action, multiple doses to lower FBG levels which may delay injection of F-18 FDG and scan acquisition. To perform the scan in patients with high FBG levels on the same day in a remote center away from cyclotron facility, we used short-acting IV insulin protocol.

The short-acting IV insulin therapy used in Group I patients worked well and lowered the mean ± SD blood glucose levels from 216 ± 22.2 to 136 ± 13.4 mg/dL, which was statistically significant with *P* \< 0.05. In a similar study done by Roy *et al*., using short-acting IV insulin therapy, the mean ± SD blood glucose levels decreased from 234 ± 36 to 126 ± 36 mg/dL.

Visual image analysis of positron emission tomography scan {#sec2-6}
----------------------------------------------------------

In Group I, 15/30 (50%) patients showed score "0," and 15/30 (50%) patients showed score "1" with decreased blood glucose levels but values remained between 130 and 160 mg/dL, mean value (148 ± 7 mg/dL); however, there was 100% acceptable image quality in all patients. Roy *et al*. documented 75% of study population with acceptable image quality and 25% with altered biodistribution manifested as increased muscular uptake (unacceptable image quality).\[[@ref6]\] Residual physiological effect of insulin might be the reason for score "1" in visual image analysis (mild muscular uptake). In our study, F-18 FDG injection was given after a gap of 90 min of insulin therapy, and all studies were of visually acceptable quality. Figures [2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"} shows the representative images of Group I, II and III patients with optimal image quality respectively.

![F-18 fluorodeoxyglucose positron emission tomography maximum intensity projection image of Group I patient with optimal image quality with visual image analysis score of 0 (no abnormal muscle and soft-tissue uptake). Postinsulin therapy, there was physiological decreased fluorodeoxyglucose concentration in brain that enhanced visualization of the left cerebellar metastases](IJNM-35-110-g002){#F2}

![F-18 fluorodeoxyglucose positron emission tomography maximum intensity projection image of Group II patient with optimal image quality with visual image analysis score of 0 (no abnormal muscle and soft-tissue uptake)](IJNM-35-110-g003){#F3}

![F-18 fluorodeoxyglucose positron emission tomography maximum intensity projection image of Group III patient with optimal image quality with visual image analysis score of 0 (no abnormal muscle and soft-tissue uptake)](IJNM-35-110-g004){#F4}

SUV and related parameters in PET technology are simple and popular tools for metabolic activity quantification in cancer sites and normal tissue. To know the effect of hyperglycemia on quantitative measurements, max SUV values of the brain, heart, liver, skeletal muscle, and fat tissue were measured in all patients, and they were compared statistically between groups.

In our study, brain max SUV (6.1 ± 1.85) in Group I patients was lower than Group II and III max SUV values (8.2 ± 2.15 and 8.7 ± 2.33), and it was statistically significant with *P* \< 0.05 \[[Table 6](#T6){ref-type="table"}\]. In Group I patients with high FBG level (\>160 mg/dL) physiologically, there will be increased competition between elevated plasma glucose and F-18 FDG for carrier enzymes to enter in the brain cell. Ishizu *et al*. studied the impact of glucose loading on visualization of brain tumors and glioma. In their study, they observed fractional decreased F-18 FDG uptake in normal brain cortex and brain tumor causing an increment in tumor to brain cortex ratio.\[[@ref13][@ref14]\] In our study also, we were able to identify and better delineate brain metastases in Group I patients \[[Figure 2](#F2){ref-type="fig"}\].

In whole-body F-18 FDG, PET CT used for cancer staging nonspecific uptake in the myocardium is a common finding which depends on the dominance of energy substrate metabolism, glucose, or free fatty acids.\[[@ref15][@ref16][@ref17]\] In Group I compared to noninsulin group \[[Table 6](#T6){ref-type="table"}\], there was significant decreased heart uptake (max SUV: 2.9 ± 1.8) which was consistent with the findings of Israel *et al*., who showed that myocardial F-18 FDG uptake was significantly lower in diabetics.\[[@ref18]\] In addition, insulin therapy and other dietary factors may also cause rapid clearance of F-18 FDG, causing decrease in circulating radiotracer available for myocardial uptake.\[[@ref19][@ref20]\]

Variations in blood glucose levels are known to affect the F-18 FDG uptake in the liver cell;\[[@ref21]\] physiologically, this is mediated by insulin-independent GLUT-2 transporters. In our study, there was no significant difference between max SUV values of liver among Group I and Group II patients. In Group III patients, liver max SUV values were 2.4 ± 0.6, which showed statistically significant difference from Group I and II values \[[Table 6](#T6){ref-type="table"}\]; however, values in all groups were within acceptable limits.

Glucose enters through insulin-dependent GLUT-4 receptors present in the cell wall of myocardial and striated muscle.\[[@ref22][@ref23]\] In our study, we observed statistically significant mild increased muscle activity in both Group I and II max SUV (1.03 ± 0.33, 0.86 ± 0.57) \[[Table 6](#T6){ref-type="table"}\]. Our results in Group II were in accordance with Hara *et al*. who reported increased muscle F-18 FDG uptake due to chronic hyperglycemia.\[[@ref24]\] Studies done by Kelley *et al*. found that glucose phosphorylation in muscles was altered in diabetic patients and that it increased in a dose-responsive manner with insulin infusion resulting in muscular uptake.\[[@ref25][@ref26]\]

During hyperglycemia, insulin lowers plasma glucose by stimulating insulin-dependent GLUT-4 receptors causing glucose uptake into skeletal muscle and adipose tissue. Hence, under insulin effect, adipose tissue also takes up F-18 FDG.\[[@ref6][@ref24]\] Fat uptake in Group I (0.48 ± 0.20) and Group II (0.40 ± 0.14) was slightly higher than the value in Group III (0.37 ± 0.17) and showed significant difference \[[Table 6](#T6){ref-type="table"}\] but well within acceptable limits. Thus, our study findings are consistent with previous studies done by Roy *et al*. and Garcia *et al*.\[[@ref6][@ref12]\]

Conclusion {#sec1-5}
==========

Using short-acting intravenous insulin therapy protocol, optimal quality F-18 FDG PET CT scan images can be obtained in patients detected with hyperglycemia on the day of test. This short-acting IV insulin therapy protocol is not only safe and easy to perform but avoids potential delay in diagnostic work up and save resources.
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